{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:32:02Z","timestamp":1787070722011,"version":"build-2736575974"},"reference-count":82,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>A significant subgroup of stroke patients require oral anticoagulants (OACs) for the prevention of recurrence of thromboembolic events. For a long time, clinicians have been using conventional warfarin as OAC in stroke prevention. However, the discovery of newer OACs that do not require strict monitoring with an international normalized ratio (INR) has resulted in changes in guidelines for stroke prevention. For the last 10 years, there has been a flood of literature on the use of Vitamin K antagonist (VKA) versus non-vitamin K antagonist oral anticoagulants (NOACs) in stroke prevention. More than 100 meta-analyses, randomized trials, and more than six new guidelines or comparisons of guidelines are available in the medical literature. Hence, we have planned to write a review on this topic to compile all new findings and recommendations. Therefore, now, clinicians have to use currently available knowledge and guidelines for choosing appropriate OAC in stroke settings. The current review is divided into 6 segments: 1) general information and protocol for VKA use; 2) current definition to describe \u201cvalvular\u201d versus \u201cnon-valvular\u201d AF; 3) to describe current recommendations for uses of VKA and NOACs for recurrent stroke prevention; 4) how to use VKA\/NOACs in special populations; 5) perioperative management of patients on OAC; and 6) OAC recommendations for Asian population. This narrative review can help for the better understanding and clear clinical decision making for selection of OAC in stroke patients. Further, it will highlight the gray areas with no clearcut guidance for the selection of OAC.<\/jats:p>","DOI":"10.4103\/bc.bc_151_24","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:00:25Z","timestamp":1750748425000},"page":"288-300","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Dealing with oral anticoagulants in stroke patients: A narrative review based on current practice guidelines"],"prefix":"10.4103","volume":"11","author":[{"given":"Deepak","family":"Goel","sequence":"first","affiliation":[{"name":"Department of Neurology, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"R1-20251229","doi-asserted-by":"crossref","first-page":"1","DOI":"10.20431\/2456-057X.0701001","article-title":"Association of poor drug adherence and recurrent stroke. An alarm for better patients and Family education","volume":"7","author":"Goel","year":"2024","journal-title":"ARC J Neurosci"},{"key":"R2-20251229","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack:A guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"R3-20251229","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2147\/PPA.S204246","article-title":"Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants:A cross-sectional study","volume":"13","author":"Ng","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"R4-20251229","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s12872-021-02295-w","article-title":"Shifting from Vitamin K antagonists to Non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation:Predictors, patterns and temporal trends","volume":"21","author":"Shiyovich","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"R5-20251229","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2011.08753.x","article-title":"Guidelines on oral anticoagulation with warfarin \u2013Fourth edition","volume":"154","author":"Keeling","year":"2011","journal-title":"Br J Haematol"},{"key":"R6-20251229","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"R7-20251229","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"R8-20251229","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"R9-20251229","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s40140-021-00511-z","article-title":"Perioperative guidelines on antiplatelet and anticoagulant agents:2022 update","volume":"12","author":"Moster","year":"2022","journal-title":"Curr Anaesthesiol Rep"},{"key":"R10-20251229","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000475","article-title":"2024 guideline for the primary prevention of stroke:A guideline from the American Heart Association\/American Stroke Association","volume":"55","author":"Bushnell","year":"2024","journal-title":"Stroke"},{"key":"R11-20251229","doi-asserted-by":"crossref","first-page":"f20","DOI":"10.1093\/ehjcvp\/pvz073","article-title":"Safety and efficacy of Non-Vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation:Systematic review and meta-analysis of 22 studies and 440 281 patients","volume":"7","author":"Silverio","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R12-20251229","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s11845-021-02891-x","article-title":"Systematic review and meta-analysis of randomized controlled trials on safety and effectiveness of oral anticoagulants for atrial fibrillation in older people","volume":"191","author":"Erdem","year":"2022","journal-title":"Ir J Med Sci"},{"key":"R13-20251229","first-page":"47","article-title":"Bleeding in anticoagulated patients with atrial fibrillation:Practical considerations","volume":"130","author":"Undas","year":"2020","journal-title":"Pol Arch Intern Med"},{"key":"R14-20251229","doi-asserted-by":"crossref","first-page":"361","DOI":"10.23736\/S0026-4725.19.04985-5","article-title":"Use of DOACs in real-world challenging settings:A Delphi consensus from Italian cardiologists","volume":"67","author":"Rossini","year":"2019","journal-title":"Minerva Cardioangiol"},{"key":"R15-20251229","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MCP.0000000000000787","article-title":"Direct oral anticoagulant use in special populations","volume":"27","author":"Lamarche","year":"2021","journal-title":"Curr Opin Pulm Med"},{"key":"R16-20251229","doi-asserted-by":"crossref","first-page":"e012540","DOI":"10.1161\/JAHA.119.012540","article-title":"Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation:A systematic review and meta-analysis","volume":"8","author":"Deng","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R17-20251229","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2459\/JCM.0000000000001041","article-title":"Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation:A meta-analysis","volume":"21","author":"Casula","year":"2020","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"R18-20251229","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0039-3400300","article-title":"Efficacy and safety of nonvitamin k oral anticoagulants in patients with atrial fibrillation and cancer:A study-level meta-analysis","volume":"120","author":"Cavallari","year":"2020","journal-title":"Thromb Haemost"},{"key":"R19-20251229","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10741-019-09844-8","article-title":"Efficacy and safety of oral anticoagulants in atrial fibrillation patients with cancer-a network meta-analysis","volume":"25","author":"Yang","year":"2020","journal-title":"Heart Fail Rev"},{"key":"R20-20251229","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00228-021-03132-x","article-title":"Safety and efficacy of new oral anticoagulants compared to those of warfarin in AF patients with cancer:A meta-analysis of randomized clinical trials and observational studies","volume":"77","author":"Chen","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"R21-20251229","doi-asserted-by":"crossref","first-page":"101346","DOI":"10.1016\/j.cpcardiol.2022.101346","article-title":"Efficacy and safety of the non-Vitamin K antagonist oral anticoagulant among patients with nonvalvular atrial fibrillation and cancer:A systematic review and network meta-analysis","volume":"47","author":"Barbarawi","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"R22-20251229","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.3390\/jcm11195712","article-title":"Superiority of direct oral anticoagulants over Vitamin K antagonists in oncological patients with atrial fibrillation:Analysis of efficacy and safety outcomes","volume":"11","author":"Parrini","year":"2022","journal-title":"J Clin Med"},{"key":"R23-20251229","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/clc.23647","article-title":"Non-Vitamin K antagonist oral anticoagulants versus Vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage:A systematic review and meta-analysis of observational studies","volume":"44","author":"Guo","year":"2021","journal-title":"Clin Cardiol"},{"key":"R24-20251229","doi-asserted-by":"crossref","first-page":"e25216","DOI":"10.1097\/MD.0000000000025216","article-title":"The risk of gastrointestinal hemorrhage with non-Vitamin K antagonist oral anticoagulants:A network meta-analysis","volume":"100","author":"Oh","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R25-20251229","doi-asserted-by":"crossref","first-page":"10760296211064897","DOI":"10.1177\/10760296211064897","article-title":"Prevention of Non-Vitamin K Oral Anticoagulants-Related Gastrointestinal Bleeding with Acid Suppressants:A Systematic Review and Meta-Analysis","volume":"28","author":"Dong","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"R26-20251229","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.amjcard.2021.09.011","article-title":"Risk of intracranial hemorrhage caused by direct oral anticoagulants for stroke prevention in patients with atrial fibrillation (from a network meta-analysis of randomized controlled trials)","volume":"162","author":"Lv","year":"2022","journal-title":"Am J Cardiol"},{"key":"R27-20251229","first-page":"CD012144","article-title":"Antithrombotic treatment after stroke due to intracerebral haemorrhage","volume":"1","author":"Cochrane","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"R28-20251229","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/CRD.0000000000000288","article-title":"Restarting oral anticoagulation in patients with atrial fibrillation after an intracranial hemorrhage","volume":"28","author":"Nguyen","year":"2020","journal-title":"Cardiol Rev"},{"key":"R29-20251229","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1212\/CPJ.0000000000000425","article-title":"Anticoagulation for atrial fibrillation after intracranial hemorrhage:A systematic review","volume":"8","author":"Hawkes","year":"2018","journal-title":"Neurol Clin Pract"},{"key":"R30-20251229","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11883-018-0733-y","article-title":"Anticoagulation resumption after intracerebral hemorrhage","volume":"20","author":"Li","year":"2018","journal-title":"Curr Atheroscler Rep"},{"key":"R31-20251229","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jtha.2023.10.020","article-title":"Between a rock and a hard place:Resumption of oral anticoagulant therapy after intracranial hemorrhage","volume":"22","author":"Grainger","year":"2024","journal-title":"J Thromb Haemost"},{"key":"R32-20251229","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(23)00315-0","article-title":"Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH):Prospective, individual participant data meta-analysis of randomised trials","volume":"22","author":"Al-Shahi Salman","year":"2023","journal-title":"Lancet Neurol"},{"key":"R33-20251229","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(23)02025-1","article-title":"Anticoagulation in patients with cerebral amyloid angiopathy","volume":"402","author":"Shoamanesh","year":"2023","journal-title":"Lancet"},{"key":"R34-20251229","doi-asserted-by":"crossref","first-page":"e2421","DOI":"10.1212\/WNL.0000000000007534","article-title":"Oral anticoagulation in patients with chronic kidney disease:A systematic review and meta-analysis","volume":"92","author":"Malhotra","year":"2019","journal-title":"Neurology"},{"key":"R35-20251229","doi-asserted-by":"crossref","first-page":"2683740","DOI":"10.1155\/2020\/2683740","article-title":"Efficacy and Safety of Non-Vitamin K Anticoagulants for Atrial Fibrillation about different Renal Function Levels:A Network Meta-Analysis","volume":"2020","author":"Jin","year":"2020","journal-title":"Cardiovasc Ther"},{"key":"R36-20251229","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.carrev.2020.09.041","article-title":"Safety and efficacy of apixaban, rivaroxaban, and warfarin in end-stage renal disease with atrial fibrillation:A systematic review and meta-analysis","volume":"30","author":"Abdullah","year":"2021","journal-title":"Cardiovasc Revasc Med"},{"key":"R37-20251229","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40261-021-01016-7","article-title":"Efficacy and safety of direct oral anticoagulants versus warfarin in patients with chronic kidney disease and dialysis patients:A systematic review and meta-analysis","volume":"41","author":"Chen","year":"2021","journal-title":"Clin Drug Investig"},{"key":"R38-20251229","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10557-020-07108-4","article-title":"Effectiveness and safety of direct oral anticoagulants in an Asian population with atrial fibrillation undergoing dialysis:A population-based cohort study and meta-analysis","volume":"35","author":"See","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"R39-20251229","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.ajkd.2021.02.328","article-title":"Oral anticoagulant agents in patients with atrial fibrillation and CKD:A systematic review and pairwise network meta-analysis","volume":"78","author":"Su","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"R40-20251229","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.dld.2018.12.001","article-title":"Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis:A systematic review and meta-analysis","volume":"51","author":"Chokesuwattanaskul","year":"2019","journal-title":"Dig Liver Dis"},{"key":"R41-20251229","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/clc.23408","article-title":"Real-world use of nonvitamin K antagonist oral anticoagulant in atrial fibrillation patients with liver disease:A meta-analysis","volume":"43","author":"Dai","year":"2020","journal-title":"Clin Cardiol"},{"key":"R42-20251229","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40256-019-00369-x","article-title":"Non-Vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and liver disease:A meta-analysis and systematic review","volume":"20","author":"Fu","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"R43-20251229","doi-asserted-by":"crossref","first-page":"e14585","DOI":"10.1111\/ijcp.14585","article-title":"Warfarin compared with non-Vitamin K antagonist oral anticoagulants in subjects with liver disease and atrial fibrillation:A meta-analysis","volume":"75","author":"Su","year":"2021","journal-title":"Int J Clin Pract"},{"key":"R44-20251229","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-021-00482-w","article-title":"Comparison of the efficacy and safety of direct oral anticoagulants and Vitamin K antagonists in patients with atrial fibrillation and concomitant liver cirrhosis:A systematic review and meta-analysis","volume":"22","author":"Lee","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"R45-20251229","doi-asserted-by":"crossref","first-page":"44","DOI":"10.18773\/austprescr.2015.016","article-title":"How to manage warfarin therapy","volume":"38","author":"Tideman","year":"2015","journal-title":"Aust Prescr"},{"key":"R46-20251229","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1055\/s-0037-1615385","article-title":"Warfarin or acenocoumarol:Which is better in the management of oral anticoagulants?","volume":"80","author":"Barcellona","year":"1998","journal-title":"Thromb Haemost"},{"key":"R47-20251229","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/bmj.288.6426.1268","article-title":"Flexible induction dose regimen for warfarin and prediction of maintenance dose","volume":"288","author":"Fennerty","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"R48-20251229","article-title":"Oxford University Hospital, (NHS Foundation Trust, Oxford Hemophilia and Thrombosis Center Protocols for Outpatient oral Anticoagulation with Vitamin K Antagonists","author":"Shapiro","year":"2017","journal-title":"AC Protocol Version 4.1"},{"key":"R49-20251229","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000314936","article-title":"Warfarin knowledge in patients with atrial fibrillation:Implications for safety, efficacy, and education strategies","volume":"116","author":"Smith","year":"2010","journal-title":"Cardiology"},{"key":"R50-20251229","doi-asserted-by":"crossref","first-page":"280","DOI":"10.5414\/CPP46280","article-title":"Patient knowledge on oral anticoagulants:Results of a questionnaire survey in Germany and comparison with the literature","volume":"46","author":"Jank","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R51-20251229","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijcard.2005.07.031","article-title":"Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy:Effects of an educational intervention programme. The West Birmingham atrial fibrillation project","volume":"110","author":"Lane","year":"2006","journal-title":"Int J Cardiol"},{"key":"R52-20251229","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0140-6736(11)61294-4","article-title":"Self-monitoring of oral anticoagulation:Systematic review and meta-analysis of individual patient data","volume":"379","author":"Heneghan","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"R53-20251229","first-page":"CD003839","article-title":"Self-monitoring and self-management of oral anticoagulation","volume":"5","author":"Heneghan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R54-20251229","first-page":"474","article-title":"Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation","volume":"16","author":"Balc\u0131","year":"2016","journal-title":"Anatol J Cardiol"},{"key":"R55-20251229","doi-asserted-by":"crossref","first-page":"e0234734","DOI":"10.1371\/journal.pone.0234734","article-title":"Determinants of health-related quality of life among warfarin patients in Pakistan","volume":"15","author":"Iqbal","year":"2020","journal-title":"PLoS One"},{"key":"R56-20251229","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1016\/j.jacc.2019.04.039","article-title":"Valvular atrial fibrillation:A confusing and obsolete definition","volume":"73","author":"Giancaterino","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R57-20251229","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/VHRM.S387477","article-title":"Thromboembolism and major bleeding in patients with atrial fibrillation and EHRA type 2 valvular heart disease:The jordan atrial fibrillation (JoFib) study","volume":"19","author":"Al-Najar","year":"2023","journal-title":"Vasc Health Risk Manag"},{"key":"R58-20251229","doi-asserted-by":"crossref","first-page":"764356","DOI":"10.3389\/fcvm.2021.764356","article-title":"Direct acting oral anticoagulant versus warfarin in the prevention of thromboembolism in patients with non-valvular atrial fibrillation with valvular heart disease \u2013A systematic review and meta-analysis","volume":"8","author":"Martha","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R59-20251229","doi-asserted-by":"crossref","DOI":"10.1177\/17539447221093963","article-title":"Direct oral anticoagulation in atrial fibrillation and heart valve surgery \u2013A meta-analysis and systematic review","volume":"16","author":"Gerfer","year":"2022","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"R60-20251229","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/europace\/eux240","article-title":"Antithrombotic therapy in atrial fibrillation associated with valvular heart disease:A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci\u00f3n Card\u00edaca y Electrofisiolog\u00eda (SOLEACE)","volume":"19","author":"Lip","year":"2017","journal-title":"Europace"},{"key":"R61-20251229","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1161\/STROKEAHA.120.032060","article-title":"New avenues for optimal treatment of atrial fibrillation and stroke prevention","volume":"52","author":"De Marchis","year":"2021","journal-title":"Stroke"},{"key":"R62-20251229","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00392-022-01996-2","article-title":"Comparative effectiveness and safety of non-Vitamin K antagonists for atrial fibrillation in clinical practice:GLORIA-AF registry","volume":"111","author":"Lip","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"R63-20251229","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ehjcvp\/pvz086","article-title":"Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation:A nationwide cohort study","volume":"6","author":"Rutherford","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R64-20251229","doi-asserted-by":"crossref","first-page":"i3189","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-Vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation:Propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"key":"R65-20251229","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/bloodadvances.2020003560","article-title":"Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation:Results from the GARFIELD-AF registry","volume":"5","author":"Bassand","year":"2021","journal-title":"Blood Adv"},{"key":"R66-20251229","first-page":"101126","article-title":"Risk of stroke or systemic embolism in patients with degenerative mitral stenosis with or without atrial fibrillation:A cohort study","volume":"43","author":"Steiner","year":"2022","journal-title":"Int J Cardiol Heart Vasc"},{"key":"R67-20251229","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2020.0652","article-title":"Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi","volume":"5","author":"Robinson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R68-20251229","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/STR.0b013e3181f7d043","article-title":"Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack:A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Furie","year":"2011","journal-title":"Stroke"},{"key":"R69-20251229","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cardfail.2004.02.006","article-title":"The warfarin and antiplatelet therapy in heart failure trial (WATCH):Rationale, design, and baseline patient characteristics","volume":"10","author":"Massie","year":"2004","journal-title":"J Card Fail"},{"key":"R70-20251229","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cardfail.2005.07.007","article-title":"Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF):Rationale, objectives, and design","volume":"12","author":"Pullicino","year":"2006","journal-title":"J Card Fail"},{"key":"R71-20251229","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"R72-20251229","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","article-title":"Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease","volume":"379","author":"Zannad","year":"2018","journal-title":"N Engl J Med"},{"key":"R73-20251229","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.athoracsur.2021.03.033","article-title":"STS\/SCA\/AmSECT\/SABM update to the clinical practice guidelines on patient blood management","volume":"112","author":"Tibi","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"R74-20251229","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/AAP.0000000000000763","article-title":"Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy:American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition)","volume":"43","author":"Horlocker","year":"2018","journal-title":"Reg Anesth Pain Med"},{"key":"R75-20251229","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"R76-20251229","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.3390\/ijerph20075293","article-title":"Perioperative management of antithrombotic therapy in patients who undergo dental procedures:A systematic review of the literature and network meta-analysis","volume":"20","author":"Boccatonda","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"R77-20251229","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"key":"R78-20251229","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2022.03.037","article-title":"RIvaroxaban in mitral stenosis (RISE MS):A pilot randomized clinical trial","volume":"356","author":"Sadeghipour","year":"2022","journal-title":"Int J Cardiol"},{"key":"R79-20251229","doi-asserted-by":"crossref","first-page":"e038194","DOI":"10.1136\/bmjopen-2020-038194","article-title":"Protocol, rationale and design of DAbigatran for stroke PreVention in atrial fibrillation in MoDerate or severe mitral stenosis (DAVID-MS):A randomised, open-label study","volume":"10","author":"Zhou","year":"2020","journal-title":"BMJ Open"},{"key":"R80-20251229","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4070\/kcj.2018.0190","article-title":"Stroke prevention in atrial fibrillation:Focus on Asian patients","volume":"48","author":"Li","year":"2018","journal-title":"Korean Circ J"},{"key":"R81-20251229"},{"key":"R82-20251229","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","article-title":"Non-Vitamin K antagonist oral anticoagulants for stroke prevention in Asian Patients with nonvalvular atrial fibrillation:Meta-analysis","volume":"46","author":"Wang","year":"2015","journal-title":"Stroke"}],"container-title":["Brain Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_151_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:35:26Z","timestamp":1787067326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_151_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/bc.bc_151_24","relation":{},"ISSN":["2394-8108","2455-4626"],"issn-type":[{"value":"2394-8108","type":"print"},{"value":"2455-4626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"2024-10-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}